EAU 2013 - Programme Book - YouMed

Monday
Monday, 18 March - EAU Programme
272 Programme Book
Abstract Session
12.15 - 13.45 Prostate cancer: Biomarkers
Silver Hall - Level N2
Poster Session 70
Chairs: S. Crouzet, Lyon (FR)
A. Haese, Hamburg (DE)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion.
848 Clinical performance of serum isoform [-2]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI
(Prostate Health Index) in men with family history of prostate cancer. Results from a multicentric European
study (PROMEtheuS project)
M. Lazzeri, G. Lughezzani, G. Lista, A. Larcher, A. Cestari, N. Buffi, A. Haese, A. Renter, A. De La Taille,
P.O. Bosset, P. Le Corvoisier, T. McNicholas, L. Fowler, J.W. Roux, J. Palou, A. Breda, P. De La Torre, V. Bini,
M. Graefen, G. Guazzoni (Milan, Perugia, Italy; Hamburg, Germany; Creteil, France; Stevenage, United
Kingdom; Barcelona, Spain)
849 Decreasing cancer specific PSA density (CaPSAD) is a hallmark of local prostate tumour progression
with prognostic relevance independent of serum PSA, and reflects a systematic alteration in androgen
signalling
N.M. Corcoran, M.K.H. Hong, N. Sapre, C.J. Nowell, J. Pedersen, G. Macintyre, R.K. Gaire, A. Kowalczyk,
L.M. Harewood, J.S. Peters, A.J. Costello, C.M. Hovens (Melbourne, Australia)
850 A prediction based on levels of four kallikrein markers in blood improves preoperative prediction of
indolent versus
S. Carlsson, A. Maschino, E. Steyerberg, T. Van Der Kwast, A. Van Leenders, A. Vickers, H. Lilja, M. Roobol
(New York, United States of America; Rotterdam, The Netherlands)
851 Lower PCA3 scores in prostate cancer patients with metastatic disease than in patients with nonmetastatic
disease: Baseline data from the Triptocare study
L. Martínez-Piñeiro, J. Schalken, A. De La Taille (Madrid, Spain; Nijmegen, The Netherlands; Creteil, France)
852 Cost evaluation of introducing the Prostate Health Index (phi) in the management of prostate cancer
diagnostic
C. Castelli, R. Mathieu, T. Fardoun, K. Bensalah, S. Vincendeau (Nimes, Rennes, France)
853 [-2]proPSA and prostate health index (phi) improve detection of prostate cancer at initial and repeated
biopsies in young men (≤ 60 year old) preferentially detecting clinically significant cancer
C. Stephan, S. Vincendeau, A. Houlgatte, K. Miller, A. Semjonow (Berlin, Münster, Germany; Rennes, Paris,
France)
854 PSA determinations with microfluidics: A novel point-of-service bioassay
M.S. Zappala, J. Libertino, A. Wein, E.D. Vaughan, P. Scardino (Andover, Burlington, Philadelphia, New York,
United States of America)
855 Definition of the Limit of Detection (LoD) for serum isoform [-2]proPSA in patients with recurrent prostate
cancer after radical prostatectomy: An analytic study
F. Ceriotti, M. Pontillo, L. Fasoli, M. Lazzeri, G. Lughezzani, G. Lista, A. Larcher, A. Cestari, N. Buffi, G. Fuzzi,
G. Guazzoni (Milan, Florence, Italy)